Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23975373)

  • 1. A let-7 KRAS rs712 polymorphism increases colorectal cancer risk.
    Pan XM; Sun RF; Li ZH; Guo XM; Zhang Z; Qin HJ; Xu GH; Gao LB
    Tumour Biol; 2014 Jan; 35(1):831-5. PubMed ID: 23975373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer.
    Huang X; Yang Y; Guo Y; Cao ZL; Cui ZW; Hu TC; Gao LB
    Genet Mol Res; 2015 Dec; 14(4):16913-20. PubMed ID: 26681038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer.
    Li ZH; Pan XM; Han BW; Guo XM; Zhang Z; Jia J; Gao LB
    Tumour Biol; 2013 Oct; 34(5):3159-63. PubMed ID: 23729275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer.
    Smits KM; Paranjape T; Nallur S; Wouters KA; Weijenberg MP; Schouten LJ; van den Brandt PA; Bosman FT; Weidhaas JB; van Engeland M
    Clin Cancer Res; 2011 Dec; 17(24):7723-31. PubMed ID: 21994416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of association between let-7 binding site polymorphism rs712 and risk of nasopharyngeal carcinoma.
    Pan XM; Jia J; Guo XM; Li ZH; Zhang Z; Qin HJ; Xu GH; Gao LB
    Fam Cancer; 2014 Mar; 13(1):93-7. PubMed ID: 23996697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer.
    Jin H; Liang Y; Wang X; Zhu J; Sun R; Chen P; Nie X; Gao L; Zhang L
    Med Oncol; 2014 Oct; 31(10):221. PubMed ID: 25201577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significant association between Let-7-KRAS rs712 G > T polymorphism and cancer risk in the Chinese population: a meta-analysis.
    Du XY; Hu YY; Xie C; Deng CY; Liu CY; Luo ZG; Niu YM; Shen M
    Oncotarget; 2017 Feb; 8(8):13863-13871. PubMed ID: 28099923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPD.
    Hu H; Zhang L; Teng G; Wu Y; Chen Y
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1641-9. PubMed ID: 26316738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single nuclear polymorphism in let-7g binding site affects the doubling time of thyroid nodule by regulating KRAS-induced cell proliferation.
    Liu A; Zhang W; Zhao T; Xiao M; Mei Q; Zhu H
    J Cell Physiol; 2019 Dec; 234(12):23437-23447. PubMed ID: 31152438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of rs712 polymorphism in a let-7 microRNA-binding site of
    Gallegos-Arreola MP; Zúñiga-González GM; Gómez-Mariscal K; Rosales-Reynoso MA; Luis L; Puebla-Pérez AM; Pineda-Razo T
    Iran J Basic Med Sci; 2019 Mar; 22(3):324-327. PubMed ID: 31156795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of rs712 polymorphism in Kras gene 3'-luntranslated region and cancer risk: a meta-analysis.
    Zhao WH; Qu XF; Xing ZG; Zhao LQ; Qin L; Lv C
    J BUON; 2015; 20(1):309-16. PubMed ID: 25778332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. rs712 polymorphism within let-7 microRNA-binding site might be involved in the initiation and progression of colorectal cancer in Chinese population.
    Jiang QH; Peng HX; Zhang Y; Tian P; Xi ZL; Chen H
    Onco Targets Ther; 2015; 8():3041-5. PubMed ID: 26543374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association analysis of miRNA-related genetic polymorphisms in miR-143/145 and KRAS with colorectal cancer susceptibility and survival.
    Wang D; Liu Q; Ren Y; Zhang Y; Wang X; Liu B
    Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33825830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
    Kjersem JB; Ikdahl T; Guren T; Skovlund E; Sorbye H; Hamfjord J; Pfeiffer P; Glimelius B; Kersten C; Solvang H; Tveit KM; Kure EH
    BMC Cancer; 2012 Nov; 12():534. PubMed ID: 23167843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An let-7 KRAS rs712 polymorphism increases hepatocellular carcinoma risk.
    Xiong D; Song YP; Xiong W; Liang YD
    Genet Mol Res; 2015 Oct; 14(4):14050-5. PubMed ID: 26535719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis.
    Schneiderova M; Naccarati A; Pardini B; Rosa F; Gaetano CD; Jiraskova K; Opattova A; Levy M; Veskrna K; Veskrnova V; Buchler T; Landi S; Vodicka P; Vymetalkova V
    Mutagenesis; 2017 Oct; 32(5):533-542. PubMed ID: 29048575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Functional Polymorphism in the Promoter of MiR-143/145 Is Associated With the Risk of Cervical Squamous Cell Carcinoma in Chinese Women: A Case-Control Study.
    Liang Y; Sun R; Li L; Yuan F; Liang W; Wang L; Nie X; Chen P; Zhang L; Gao L
    Medicine (Baltimore); 2015 Aug; 94(31):e1289. PubMed ID: 26252302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells.
    Luu C; Heinrich EL; Duldulao M; Arrington AK; Fakih M; Garcia-Aguilar J; Kim J
    PLoS One; 2013; 8(8):e70604. PubMed ID: 23936455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS polymorphisms are associated with survival of CRC in Chinese population.
    Dai Q; Wei HL; Huang J; Zhou TJ; Chai L; Yang ZH
    Tumour Biol; 2016 Apr; 37(4):4727-34. PubMed ID: 26515332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
    Graziano F; Canestrari E; Loupakis F; Ruzzo A; Galluccio N; Santini D; Rocchi M; Vincenzi B; Salvatore L; Cremolini C; Spoto C; Catalano V; D'Emidio S; Giordani P; Tonini G; Falcone A; Magnani M
    Pharmacogenomics J; 2010 Oct; 10(5):458-64. PubMed ID: 20177422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.